Intellia Therapeutics, Inc. 8-K

What Happened
Intellia Therapeutics (NTLA) announced on June 13, 2026 (press release furnished as Exhibit 99.1 and published in the New England Journal of Medicine) additional positive results from the global Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z, formerly NTLA-2002) for hereditary angioedema (HAE). The trial met its primary endpoint with an 87% reduction (p<0.0001) in mean monthly attacks for lonvo-z vs. placebo during weeks 5–28. Key secondary results reported: 62% of patients on lonvo-z were attack-free and therapy-free for the six-month efficacy period versus 11% on placebo (p<0.0001). Other outcomes included an 89% reduction in monthly attacks requiring on-demand treatment (0.19 vs. 1.79) and a 91% reduction in moderate/severe attacks (0.11 vs. 1.23). Safety was favorable—most common TEAEs were infusion-related reaction, headache, fatigue, back pain, and upper respiratory infection; events were mild/moderate and no serious adverse events were observed in the lonvo-z arm. Data cutoff was February 10, 2026.

Key Details

• Trial arms: lonvo-z N=52; placebo N=28.
• Primary endpoint: 87% reduction in mean monthly attacks (p<0.0001; weeks 5–28).
• Selected secondary endpoints: 89% reduction in attacks requiring on-demand treatment; 91% reduction in moderate/severe attacks; AE-QoL improvement of -23.51 vs -6.47 (mean change -17.04, p<0.0001).
• Regulatory status: rolling BLA submission to FDA initiated in April 2026; company continues to anticipate U.S. approval and launch in first half of 2027.

Why It Matters
These results support the case that lonvo-z could be a one-time gene-editing-based therapy that substantially reduces or eliminates HAE attacks for many patients, which—if approved—would represent a large clinical and commercial opportunity distinct from current chronic prophylactic therapies. The filing highlights strong efficacy, consistent subgroup responses, and a favorable short-term safety profile, and notes an active BLA submission and planned regulatory review. Investors should note the company’s forward-looking statements and the usual development and regulatory risks described in the filing.